Atea Pharmaceuticals Inc (AVIR)

NASDAQ
25.11
-0.42(-1.65%)
  • Volume:
    463,310
  • Bid/Ask:
    22.96/25.25
  • Day's Range:
    24.75 - 25.89

AVIR Overview

Prev. Close
25.53
Day's Range
24.75-25.89
Revenue
114.61M
Open
25.53
52 wk Range
18.73-94.17
EPS
0.25
Volume
463,310
Market Cap
2.08B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
-
P/E Ratio
99.14
Beta
-
1-Year Change
-
Shares Outstanding
82,736,937
Next Earnings Date
Dec 01, 2021
What is your sentiment on Atea Pharmaceuticals Inc?
or
Market is currently closed. Voting is open during market hours.

Atea Pharmaceuticals Inc News

Atea Pharmaceuticals Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellBuyBuyNeutralSell
Technical IndicatorsBuyBuyStrong SellStrong BuySell
SummaryNeutralBuyNeutralBuySell

Atea Pharmaceuticals Inc Company Profile

Atea Pharmaceuticals Inc Company Profile

Employees
42

Atea Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening viral infections. It is focused on development of product candidates to treat coronavirus disease (COVID-19), dengue, chronic hepatitis C (HCV), and respiratory syncytial virus (RSV). Its purine nucleotide prodrug platform develops treatments for life threatening diseases caused by single stranded ribonucleic acid (ssRNA) viral infections. Its lead product candidate, AT-527, is an orally administered, antiviral agent for the treatment of patients with COVID-19. It is developing AT-752, an oral, purine nucleoside prodrug product candidate for the treatment of dengue. It is also developing AT-787 for the treatment of chronic HCV infection, including patients with decompensated cirrhosis. It is evaluating AT-889 and other candidates for the treatment of RSV.

Read More
  • when its rebounding? why so less traction in this share
    0
    • Why drop sharply after 2nd phase success?
      0
      • I think some smart money (bonds guys) sold their shares.
        0
    • Looking good on third phase so ...
      0
      Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
      Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.